Which stock wins in a battle between a COVID-19 testing leader and the top contract manufacturer for COVID-19 vaccines?
News & Analysis: Opko Health
The company is rolling out a new COVID-19 testing program for businesses.
Its BioReference subsidiary is rolling out testing with five locations -- one in each of NYC's boroughs -- but will quickly expand its footprint.
The company's sales slipped in the quarter despite a ramp-up in COVID-19 testing demand.
And why the company still managed to meet Wall Street's earnings expectation.
BioReference Laboratories will provide the testing at the pharmacy chain's expanding network of drive-thru COVID-19 testing sites.
The company's COVID-19 tests will be available at additional Rite Aid drive-thru pharmacies, beginning April 20.
The pharmaceutical and diagnostics specialist ran into some SEC-related controversy in 2018; now, it's a major player in the fight against COVID-19.
While the spread of COVID-19 has destroyed billions of dollars of market value, stocks in healthcare companies that are fighting the virus continue to advance.
The company says its COVID-19 test is available nationwide, and it just launched a high-capacity drive-thru service in a hard-hit New York suburb.